Higher⁃risk myelodysplastic syndromes（HR⁃MDS）has a high risk of developing acute myeloid leukemia，andthe prognosis of patients is poor. The current standard treatment for HR⁃MDS includes hypomethylating agents and allogeneic hematopoietic stem cell transplantation. In recent years，the application of BCL⁃2 inhibitors has led to the rapid improvement of the treatment of HR ⁃MDS. BCL ⁃2 inhibitorscombined with multipledrugs has shown high remission rates and acceptable adverse effect rates. This articlereviews the recent therapeutic advances of Venetoclax in HR⁃MDS.